A Phase III, Observer-blind, Randomized Controlled Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
Latest Information Update: 18 Jun 2025
At a glance
- Drugs Pneumococcal 13-valent vaccine conjugate Sinovac Biotech (Primary) ; 13-Valent pneumococcal conjugate vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 18 Jun 2025 New trial record